Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Cash from Investing Activities (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Cash from Investing Activities data on record, last reported at $38.1 million in Q3 2025.

  • For Q3 2025, Cash from Investing Activities rose 1.03% year-over-year to $38.1 million; the TTM value through Sep 2025 reached -$67.7 million, down 9231.31%, while the annual FY2024 figure was -$44.5 million, 150.06% down from the prior year.
  • Cash from Investing Activities reached $38.1 million in Q3 2025 per GLUE's latest filing, up from $25.3 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $38.1 million in Q3 2025 and bottomed at -$100.2 million in Q1 2025.
  • Average Cash from Investing Activities over 3 years is $689272.7, with a median of $18.6 million recorded in 2023.
  • The widest YoY moves for Cash from Investing Activities: up 141.41% in 2025, down 1117.24% in 2025.
  • A 3-year view of Cash from Investing Activities shows it stood at $14.3 million in 2023, then plummeted by 316.1% to -$30.9 million in 2024, then surged by 223.44% to $38.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $38.1 million in Q3 2025, $25.3 million in Q2 2025, and -$100.2 million in Q1 2025.